Chair & Presenters, Grzegorz (Greg) Nowakowski, MD, Paolo F. Caimi, MD, and Stephen J. Schuster, MD, prepared useful Practice Aids pertaining to diffuse large B-cell lymphoma for this CME/MOC activity titled “Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3MMLszc. CME/MOC credit will be available until January 8, 2024.

1. Premedication Guidance to Minimize Infusion Reactions Associated With Tafasitamab
For patients not experiencing infusion reactions during the first three infusions,
premedication is optional for subsequent infusions
Tafasitamab is FDA-approved in combination with lenalidomide for the treatment of adult
patients with relapsed or refractory DLBCL-NOS, including DLBCL arising from low-grade
lymphoma, and who are not eligible for ASCT1
12 mg/kg as an IV infusion
Administer in combination with lenalidomide
(25 mg/d PO d 1-21)2
for a maximum of 12 cycles
and then continue as monotherapy until disease
progression or unacceptable toxicity
Dosing Recommendations
Cycle 1
d 1, 4, 8, 15, and 22 of the
28-d cycle
Cycles 2 and 3
d 1, 8, 15, and 22 of each
28-d cycle
Cycles 4 and beyond
d 1 and 15 of each 28-d
cycle
Premedicate 30 minutes to 2 hours
prior to starting IV infusion to minimize
infusion reactions
• Acetaminophen
• Histamine H1 receptor antagonists
• Histamine H2 receptor antagonists
• Glucocorticoids
1. Monjuvi (tafasitamab-cxix) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf. 2. Revlimid (lenalidomide) Prescribing Information. https://www.
accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf.
Dosing Recommendations and Treatment Considerations
With Antibody Options for DLBCL: Tafasitamab
Full abbreviations, accreditation, and disclosure information available at PeerView.com/ENP40

2. Tafasitamab1
+ Lenalidomide2
Dosing Schedule Tool
1. Monjuvi (tafasitamab-cxix) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf. 2. Revlimid (lenalidomide) Prescribing Information. https://www.
accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf.
Cycle 1
DAYS
Tafasitamab 12 mg/kg
Lenalidomide 25 mg daily
Cycle 2 and 3
Cycle 4 to 12
After 12 cycles, continue tafasitamab monotherapy until disease progression or unacceptable toxicity
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
DAYS
Tafasitamab 12 mg/kg
Lenalidomide 25 mg daily
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
DAYS
Tafasitamab 12 mg/kg
Lenalidomide 25 mg daily
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
DAYS
Tafasitamab 12 mg/kg
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Dosing Recommendations and Treatment Considerations
With Antibody Options for DLBCL: Tafasitamab
Full abbreviations, accreditation, and disclosure information available at PeerView.com/ENP40

3. Dosing Recommendations and Treatment Considerations
With Antibody Options for DLBCL: Polatuzumab
Full abbreviations, accreditation, and disclosure information available at PeerView.com/ENP40
Safety Monitoring Recommendations for Adverse Events Associated With Polatuzumab
Polatuzumab is FDA-approved in combination with bendamustine and rituximab (BR) for the
treatment of adult patients with relapsed or refractory DLBCL-NOS, after ≥2 prior therapies1
1.8 mg/kg as an IV infusion
Administer over 90 minutes every 21 days for
6 cycles in combination with BR2,3
• Subsequent infusions may be administered
over 30 minutes if the previous infusion
is tolerated
• Premedicate with an antihistamine and
antipyretic before infusion
Dosing Recommendations
Peripheral neuropathy
• Monitor
• Modify or discontinue dose accordingly
Infusion reactions
• Premedication recommended
• Monitor closely during infusions
• Interrupt or discontinue infusion for reactions
Myelosuppression
• Monitor complete blood count and for infections
• Manage using dose delays or reductions
• Consider prophylactic G-CSF administration
Progressive multifocal leukoencephalopathy
• Monitor for new or worsening neurological, cognitive, or
behavioral changes
Bacterial, fungal, and viral infections • Closely monitor for infections
Other monitoring recommendations: TLS and hepatotoxicity
1. Polivy (polatuzumab vedotin-piiq) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf. 2. Treanda (bendamustine hydrochloride) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022303lbl.pdf. 3. Rituxan (rituximab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5464lbl.pdf.

4. Dosing Recommendations and Treatment Considerations
With Antibody Options for DLBCL: Tafasitamab
Full abbreviations, accreditation, and disclosure information available at PeerView.com/ENP40
Loncastuximab is FDA-approved under accelerated approval for the treatment of adult patients
with relapsed or refractory large B-cell lymphoma, including DLBCL-NOS, DLBCL arising from
low-grade lymphoma, and high-grade B-cell lymphoma, after ≥2 prior therapies1
75-150 mcg/kg as an IV infusion
Administered over 30 minutes
Premedicate with dexamethasone 4 mg PO or IV twice
daily for 3 days beginning on the day before treatment
Dosing Recommendations
30-minute infusion Q3W for up to 1 year
First 2 cycles After 2 cycles
150 mcg/kg 75 mcg/kg Follow-up
Q12W for up to 3 years
Safety Monitoring Recommendations for Selected Adverse Events Associated With Loncastuximab
1. Zynlonta (loncastuximab tesirine-lpyl) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf.
• Withhold until ANC returns to ≥1 × 109
/L
Neutropenia: ANC <1 × 109
/L
• Withhold until platelet count returns to ≥50,000/mcL
Thrombocytopenia: platelet count <50,000/mcL
• Withhold until the toxicity resolves to grade ≤1
Edema or effusion: grade ≥2
• Withhold until the toxicity resolves to grade ≤1
Edema or effusion: grade ≥3
Dosing Recommendations and Treatment Considerations
With Antibody Options for DLBCL: Loncastuximab
Full abbreviations, accreditation, and disclosure information available at PeerView.com/ENP40